Innovotech Inc.

Innovotech Inc.

May 04, 2010 12:26 ET

Innovotech Announces Shareholder Rights Plan

EDMONTON, ALBERTA--(Marketwire - May 4, 2010) - Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") announced that, at its Annual and Special Meeting of the Shareholders for the financial year ending December 31, 2009 held on April 20, 2010 as scheduled, the shareholders approved the adoption of a shareholder rights plan ("Rights Plan") designed to provide its shareholders with full and fair value in the event of a possible take-over bid for its common shares. The Rights Plan has been implemented pursuant to the terms of a shareholder rights plan agreement entered into between Innovotech and Olympia Trust Company, as rights agent, dated March 1, 2010 (the "Agreement") and filed on SEDAR on March 24, 2010. The Agreement took effect immediately upon execution, subject to ratification by Innovotech's shareholders. Adoption of the Rights Plan is subject to regulatory acceptance.

The objectives of the Rights Plan are to ensure, to the extent possible, that all shareholders of Innovotech are treated equally and fairly in connection with any take-over bid or similar proposal to acquire common shares of Innovotech. As of the date of this press release, Innovotech is not aware of any third party considering or preparing any proposal to acquire control of Innovotech or of any pending or threatened take-over bid for its common shares.

Under the terms of the Rights Plan, Innovotech authorizes the issuance of one right to attach to each common share of Innovotech outstanding and any other common share in the capital stock of Innovotech or voting interests of Innovotech entitled to vote generally in the election of directors (collectively the "Voting Shares") issued thereafter subject to the limitations set forth in the Rights Plan.

Each right entitles the holder thereof, after the Separation Time, to purchase from Innovotech one common share pursuant to the terms and subject to the conditions set forth in the Rights Plan. The rights will separate from the Voting Shares to which they are attached and will become exercisable at the close of business (the "Separation Time") on the eighth trading day after the earliest of: (a) the first date of public announcement that a person and/or others associated, affiliated or otherwise connected to such person, or acting in concert with such person, have become an Acquiring Person; (b) the date of commencement of, or first public announcement of the intent of any person to commence a take-over bid, other than a Permitted Bid or a Competing Permitted Bid, or such later date as the board may determine in good faith, and (c) the date upon which a Permitted Bid or a Competing Permitted Bid ceases to be such. Subject to adjustment as provided in the Rights Plan, each right entitles the holder to purchase one common share for an exercise price (the "Exercise Price") equal to one-quarter (1/4) of the market price per common share as such is determined as at the Separation Time.

The acquisition by any person (an "Acquiring Person") of 20% or more of the common shares, other than by way of a Permitted Bid, is referred to as a "Flip-in Event". Any Rights held by an Acquiring Person will become void upon the occurrence of a Flip-in Event.

At the close of business on the tenth trading day after the first public announcement that an Acquired Person (beneficial owner of 20% or more of the outstanding voting shares) has become such, the Rights (other than those held by the Acquiring Person) will entitle the holder to purchase Voting Shares having an aggregate market price (based on the prevailing Market Price as defined in the Shareholder Rights Agreement) equal to twice the Exercise Price for an amount in cash equal to the Exercise Price.

A Permitted Bid must remain open for acceptance for not less than 60 days and must be made through a take-over bid circular prepared in compliance with applicable securities laws and certain other conditions of the Rights Plan.

All capitalized terms without definition have the meanings attributed to them in the Rights Plan unless otherwise indicated.

About Innovotech Inc.:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information